Nature Communications (Jun 2024)
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
- Samira Salihovic,
- Niklas Nyström,
- Charlotte Bache-Wiig Mathisen,
- Robert Kruse,
- Christine Olbjørn,
- Svend Andersen,
- Alexandra J. Noble,
- Maria Dorn-Rasmussen,
- Igor Bazov,
- Gøri Perminow,
- Randi Opheim,
- Trond Espen Detlie,
- Gert Huppertz-Hauss,
- Charlotte R. H. Hedin,
- Marie Carlson,
- Lena Öhman,
- Maria K. Magnusson,
- Åsa V. Keita,
- Johan D. Söderholm,
- Mauro D’Amato,
- Matej Orešič,
- Vibeke Wewer,
- Jack Satsangi,
- Carl Mårten Lindqvist,
- Johan Burisch,
- Holm H. Uhlig,
- Dirk Repsilber,
- Tuulia Hyötyläinen,
- Marte Lie Høivik,
- Jonas Halfvarson
Affiliations
- Samira Salihovic
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University
- Niklas Nyström
- Department of Women’s and Children’s Health, Uppsala University
- Charlotte Bache-Wiig Mathisen
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo
- Robert Kruse
- Department of Clinical Research Laboratory, Faculty of Medicine and Health, Örebro University
- Christine Olbjørn
- Department of Pediatrics and Adolescent Medicine, Akershus University Hospital
- Svend Andersen
- Department of Pediatrics, Vestfold Hospital Trust
- Alexandra J. Noble
- Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford
- Maria Dorn-Rasmussen
- Department of Paediatric and Adolescence Medicine, Copenhagen University Hospital - Amager and Hvidovre
- Igor Bazov
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University
- Gøri Perminow
- Department of Pediatric Medicine, Oslo University Hospital
- Randi Opheim
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo
- Trond Espen Detlie
- Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway and Faculty of Medicine, University of Oslo
- Gert Huppertz-Hauss
- Department of Gastroenterology, Telemark Hospital Trust
- Charlotte R. H. Hedin
- Karolinska Institutet, Department of Medicine Solna
- Marie Carlson
- Department of Medical Sciences, Uppsala University
- Lena Öhman
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
- Maria K. Magnusson
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
- Åsa V. Keita
- Department of Biomedical and Clinical Sciences, Linköping University
- Johan D. Söderholm
- Department of Biomedical and Clinical Sciences, Linköping University
- Mauro D’Amato
- IKERBASQUE, Basque Foundation for Science
- Matej Orešič
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University
- Vibeke Wewer
- Department of Paediatric and Adolescence Medicine, Copenhagen University Hospital - Amager and Hvidovre
- Jack Satsangi
- Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford
- Carl Mårten Lindqvist
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University
- Johan Burisch
- Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital - Amager and Hvidovre
- Holm H. Uhlig
- Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford
- Dirk Repsilber
- School of Medical Sciences, Faculty of Medicine and Health, Örebro University
- Tuulia Hyötyläinen
- School of Science and Technology, Örebro University
- Marte Lie Høivik
- Department of Gastroenterology, Oslo University Hospital, Oslo, Norway and Faculty of Medicine, University of Oslo
- Jonas Halfvarson
- Department of Gastroenterology, Faculty of Medicine and Health, Örebro University
- DOI
- https://doi.org/10.1038/s41467-024-48763-7
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 15
Abstract
Abstract Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.
